89 related articles for article (PubMed ID: 15249209)
1. Glypican-1 antisense transfection modulates TGF-beta-dependent signaling in Colo-357 pancreatic cancer cells.
Li J; Kleeff J; Kayed H; Felix K; Penzel R; Büchler MW; Korc M; Friess H
Biochem Biophys Res Commun; 2004 Aug; 320(4):1148-55. PubMed ID: 15249209
[TBL] [Abstract][Full Text] [Related]
2. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer.
Kleeff J; Ishiwata T; Maruyama H; Friess H; Truong P; Büchler MW; Falb D; Korc M
Oncogene; 1999 Sep; 18(39):5363-72. PubMed ID: 10498890
[TBL] [Abstract][Full Text] [Related]
3. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells.
Matsuda K; Maruyama H; Guo F; Kleeff J; Itakura J; Matsumoto Y; Lander AD; Korc M
Cancer Res; 2001 Jul; 61(14):5562-9. PubMed ID: 11454708
[TBL] [Abstract][Full Text] [Related]
4. Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer.
Kleeff J; Maruyama H; Friess H; Büchler MW; Falb D; Korc M
Biochem Biophys Res Commun; 1999 Feb; 255(2):268-73. PubMed ID: 10049697
[TBL] [Abstract][Full Text] [Related]
5. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.
Rowland-Goldsmith MA; Maruyama H; Kusama T; Ralli S; Korc M
Clin Cancer Res; 2001 Sep; 7(9):2931-40. PubMed ID: 11555612
[TBL] [Abstract][Full Text] [Related]
6. A kunitz-type protease inhibitor bikunin disrupts ligand-induced oligomerization of receptors for transforming growth factor (TGF)-beta and subsequently suppresses TGF-beta signalings.
Yagyu T; Kobayashi H; Wakahara K; Matsuzaki H; Kondo T; Kurita N; Sekino H; Inagaki K; Suzuki M; Kanayama N; Terao T
FEBS Lett; 2004 Oct; 576(3):408-16. PubMed ID: 15498571
[TBL] [Abstract][Full Text] [Related]
7. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
8. Chronic exposure of transforming growth factor beta 1 confers a more aggressive tumor phenotype through downregulation of p21(WAF1/CIP1) in conditionally immortalized pancreatic epithelial cells.
Ito D; Fujimoto K; Doi R; Koizumi M; Toyoda E; Mori T; Kami K; Kawaguchi Y; Whitehead R; Imamura M
Surgery; 2004 Aug; 136(2):364-74. PubMed ID: 15300203
[TBL] [Abstract][Full Text] [Related]
9. Correlation of glypican-1 expression with TGF-beta, BMP, and activin receptors in pancreatic ductal adenocarcinoma.
Kayed H; Kleeff J; Keleg S; Jiang X; Penzel R; Giese T; Zentgraf H; Büchler MW; Korc M; Friess H
Int J Oncol; 2006 Nov; 29(5):1139-48. PubMed ID: 17016645
[TBL] [Abstract][Full Text] [Related]
10. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
[TBL] [Abstract][Full Text] [Related]
11. Upstream stimulatory factor regulates E box-dependent PAI-1 transcription in human epidermal keratinocytes.
Allen RR; Qi L; Higgins PJ
J Cell Physiol; 2005 Apr; 203(1):156-65. PubMed ID: 15372465
[TBL] [Abstract][Full Text] [Related]
12. Stable transfection of a glypican-1 antisense construct decreases tumorigenicity in PANC-1 pancreatic carcinoma cells.
Kleeff J; Wildi S; Kumbasar A; Friess H; Lander AD; Korc M
Pancreas; 1999 Oct; 19(3):281-8. PubMed ID: 10505759
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitor type-1 gene expression and induced migration in TGF-beta1-stimulated smooth muscle cells is pp60(c-src)/MEK-dependent.
Samarakoon R; Higgins CE; Higgins SP; Kutz SM; Higgins PJ
J Cell Physiol; 2005 Jul; 204(1):236-46. PubMed ID: 15622520
[TBL] [Abstract][Full Text] [Related]
14. TGF-beta 1-induced PAI-1 expression is E box/USF-dependent and requires EGFR signaling.
Kutz SM; Higgins CE; Samarakoon R; Higgins SP; Allen RR; Qi L; Higgins PJ
Exp Cell Res; 2006 Apr; 312(7):1093-105. PubMed ID: 16457817
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.
Medicherla S; Li L; Ma JY; Kapoun AM; Gaspar NJ; Liu YW; Mangadu R; O'Young G; Protter AA; Schreiner GF; Wong DH; Higgins LS
Anticancer Res; 2007; 27(6B):4149-57. PubMed ID: 18229422
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor-beta1 and activin A generate antiproliferative signaling in thyroid cancer cells.
Matsuo SE; Leoni SG; Colquhoun A; Kimura ET
J Endocrinol; 2006 Jul; 190(1):141-50. PubMed ID: 16837618
[TBL] [Abstract][Full Text] [Related]
17. Smad4 silencing in pancreatic cancer cell lines using stable RNA interference and gene expression profiles induced by transforming growth factor-beta.
Jazag A; Ijichi H; Kanai F; Imamura T; Guleng B; Ohta M; Imamura J; Tanaka Y; Tateishi K; Ikenoue T; Kawakami T; Arakawa Y; Miyagishi M; Taira K; Kawabe T; Omata M
Oncogene; 2005 Jan; 24(4):662-71. PubMed ID: 15592526
[TBL] [Abstract][Full Text] [Related]
18. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
[TBL] [Abstract][Full Text] [Related]
19. Signaling cross-talk between IGF-binding protein-3 and transforming growth factor-(beta) in mesenchymal chondroprogenitor cell growth.
O'Rear L; Longobardi L; Torello M; Law BK; Moses HL; Chiarelli F; Spagnoli A
J Mol Endocrinol; 2005 Jun; 34(3):723-37. PubMed ID: 15956343
[TBL] [Abstract][Full Text] [Related]
20. The tumor suppressor KLF11 mediates a novel mechanism in transforming growth factor beta-induced growth inhibition that is inactivated in pancreatic cancer.
Buck A; Buchholz M; Wagner M; Adler G; Gress T; Ellenrieder V
Mol Cancer Res; 2006 Nov; 4(11):861-72. PubMed ID: 17114344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
